SCHEMBL17885697

SCHEMBL17885697

CCOC(=O)c1csc([C@H]2CC[C@H](C)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.52
NPC1 O15118 8/20 0.52
MAPT P10636 6/20 0.52
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CASP3 P42574 1/20 0.52
CASP7 P55210 1/20 0.52
CASP8 Q14790 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.51
CYP1A2 P05177 2/20 0.48
CYP2C19 P33261 1/20 0.48
GAA P10253 3/20 0.46
POLB P06746 2/20 0.45
PKM P14618 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
HSP90AA1 P07900 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2142237 0.94 RAB9A (0.57) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL1245930 0.89 SMN1; SMN2 (0.60) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL2142696 0.89 SMN1; SMN2 (0.56) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL28507736 0.88 RAB9A (0.51) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL996638 0.88 SMN1; SMN2 (0.62) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL21679349 0.87 SMN1; SMN2 (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL3435708 0.86 RAB9A (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL2077891 0.85 CASP3 (0.54) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL1228518 0.85 BAZ2A (0.52) RAB9ANPC1MAPTALDH1A1MEN1
SCHEMBL3435742 0.84 RAB9A (0.50) RAB9ANPC1MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160185768-A1 THIAZOLE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185768-A1 THIAZOLE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR RAB9A 2797/4885NPC1 586/4885MAPT 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.